Advanced biopharma for animal health

The problem

Monoclonal antibodies and similar biological medicines have yet to translate into veterinary medicine fully.

The solution

Acting as a bridge between the most advanced capabilities in discovery, development, and manufacturing from the human pharma ecosystem, translating these capabilities into a world-leading bio-pharma platform for veterinary health.

Our engagement

Anterra incubated this company. Subsequent co-investors include F-Prime Capital, Google Ventures, Novo Holdings, Casdin Capital, Eight Roads, and Tekla Management.